NCT06872723 CPRIT: Patient Adherence to Lung Cancer Screening
| NCT ID | NCT06872723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Lung Cancer Screening |
| Study Type | OBSERVATIONAL |
| Enrollment | 340 participants |
| Start Date | 2025-03-21 |
| Primary Completion | 2029-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 340 participants in total. It began in 2025-03-21 with a primary completion date of 2029-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening.
Eligibility Criteria
Inclusion Criteria: * Current smoker or quit within the past 15 years * A 20+ pack-year smoking history * Healthy enough for treatment Exclusion Criteria: * Not applicable as our focus is on patients with an order for screening at the UTMB or UT Tyler
Contact & Investigator
Robert Volk, PHD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06872723 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Lung Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06872723 currently recruiting?
Yes, NCT06872723 is actively recruiting participants. Contact the research team at bvolk@mdanderson.org for enrollment information.
Where is the NCT06872723 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06872723 clinical trial?
NCT06872723 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Robert Volk, PHD at M.D. Anderson Cancer Center. The trial plans to enroll 340 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.